Updated 3-year overall survival data presented at the American Society of Clinical Oncology 2022 annual meeting show continued overall survival from OPDIVO + YERVOY plus limited chemotherapy
This resource provides insights from a medical oncologist who specializes in lung cancer. It includes information on an extended 3-year follow-up analysis of the Checkmate 9LA trial, with a minimum follow-up of 36.1 months. The Checkmate 9LA trial was a randomized, phase 3, open-label study that evaluated OPDIVO + YERVOY plus 2 cycles of platinum-based chemotherapy compared with 4 cycles of platinum-based chemotherapy alone as first-line therapy in patients with stage IV or recurrent non-small cell lung cancer, no known sensitizing EGFR or ALK aberrations, and an Eastern Cooperative Oncology Group performance status of 0 or 1. The trial evaluated patients regardless of PD-L1 expression and histology.